Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Debiopharm Ink Biomarker ID Deal

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Cenix's expertise in combining high-throughput screening with high-content assays in cultured human cells will be applied to identify predictive biomarkers for Debiopharm's preclinical cancer candidates. Cenix has established multiparametric microscopy-based readouts using the Definiens XD image analysis platform, which will be used in human cancer cell models to identify genes and pathways that enhance or suppress a drug's therapeutic effects.

According to the partners, "the study represents another important illustration of Debiopharm's ongoing drive to integrate cutting edge technologies and powerful post-genomic strategies towards further refining its personalized medicine approach toward the development of new therapeutics."

Financial and other terms of the deal were not disclosed.

Cenix is a preclinical contract research organization with operations in Germany, Belgium, and the US and develops reagent technologies for cell-based and in vivo applications.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.